Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Work In Process (2023 - 2025)

CorMedix has reported Work In Process over the past 3 years, most recently at $11.7 million for Q4 2025.

  • Quarterly results put Work In Process at $11.7 million for Q4 2025, up 231.38% from a year ago — trailing twelve months through Dec 2025 was $11.7 million (up 231.38% YoY), and the annual figure for FY2025 was $11.7 million, up 231.38%.
  • Work In Process reached $11.7 million in Q4 2025 per CRMD's latest filing, up from $9.1 million in the prior quarter.
  • Across five years, Work In Process topped out at $11.7 million in Q4 2025 and bottomed at $471415.0 in Q1 2024.
  • Median Work In Process over the past 3 years was $4.3 million (2025), compared with a mean of $4.7 million.
  • Peak annual rise in Work In Process hit 808.43% in 2025, while the deepest fall reached 78.61% in 2025.
  • Over 3 years, Work In Process stood at $580925.0 in 2023, then skyrocketed by 507.31% to $3.5 million in 2024, then soared by 231.38% to $11.7 million in 2025.
  • Business Quant data shows Work In Process for CRMD at $11.7 million in Q4 2025, $9.1 million in Q3 2025, and $5.2 million in Q2 2025.